Literature DB >> 12358579

Epidemiological modelling (including economic modelling) and its role in preventive drug therapy.

Danny Liew1, John J McNeil, Anna Peeters, Stephen S Lim, Theo Vos.   

Abstract

In contrast to curative therapies, preventive therapies are administered to largely healthy individuals over long periods. The risk-benefit and cost-benefit ratios are more likely to be unfavourable, making treatment decisions difficult. Drug trials provide insufficient information for treatment decisions, as they are conducted on highly selected populations over short durations, estimate only relative benefits of treatment and offer little information on risks and costs. Epidemiological modelling is a method of combining evidence from observational epidemiology and clinical trials to assist in clinical and health policy decision-making. It can estimate absolute benefits, risks and costs of long-term preventive strategies, and thus allow their precise targeting to individuals for whom they are safest and most cost-effective. Epidemiological modelling also allows explicit information about risks and benefits of therapy to be presented to patients, facilitating informed decision-making.

Entities:  

Mesh:

Year:  2002        PMID: 12358579     DOI: 10.5694/j.1326-5377.2002.tb04839.x

Source DB:  PubMed          Journal:  Med J Aust        ISSN: 0025-729X            Impact factor:   7.738


  4 in total

1.  Predicting the effectiveness of prevention: a role for epidemiological modeling.

Authors:  Helen L Walls; Anna Peeters; Christopher M Reid; Danny Liew; John J McNeil
Journal:  J Prim Prev       Date:  2008-07

Review 2.  Overview of pharmacoeconomic modelling methods.

Authors:  Zanfina Ademi; Hansoo Kim; Ella Zomer; Christopher M Reid; Bruce Hollingsworth; Danny Liew
Journal:  Br J Clin Pharmacol       Date:  2013-04       Impact factor: 4.335

3.  Epidemiological modelling of routine use of low dose aspirin for the primary prevention of coronary heart disease and stroke in those aged > or =70.

Authors:  Mark R Nelson; Danny Liew; Melanie Bertram; Theo Vos
Journal:  BMJ       Date:  2005-05-20

4.  Cost-Effectiveness Analysis of Rivaroxaban in Chinese Patients With Stable Cardiovascular Disease.

Authors:  Tianyu Feng; Zhou Zheng; Shang Gao; Jiaying Xu; Pen Cao; Huanhuan Jia; Xihe Yu
Journal:  Front Pharmacol       Date:  2022-06-20       Impact factor: 5.988

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.